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Background: Although diabetes is one of the most costly and rapidly increasing serious chronic diseases
worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined.
Methods: Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration,
mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on
future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a “high-risk” strategy, wherein adults
with both impaired fasting glucose (IFG) (fasting plasma glucose of 100–124 mg/dl) and impaired glucose tolerance
(IGT) (2-hour post-load glucose of 141–199 mg/dl) receive structured lifestyle intervention; 3) a “moderate-risk”
strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a “population-wide” strategy, in
which the entire population is exposed to broad risk reduction policies; and 5) a “combined” strategy, involving
both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies
reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the
population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US
population.
Results: We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6
million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is
projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence
by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%,
respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate
that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3%
in 2030).
Conclusions: While implementation of appropriate diabetes prevention strategies may slow the rate of increase of
the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase
dramatically over the next 20 years. Demand for health care services for people with diabetes complications and
diabetes-related disability will continue to grow, and these services will need to be strengthened along with
primary diabetes prevention efforts.* Correspondence: edg7@cdc.gov
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International surveillance data have documented a steady
rise in diabetes prevalence over the past 40 years in virtu-
ally all regions of the world [1,2]. Although the increases
in prevalence are, in part, due to increasing survival of
persons with diabetes, national surveys have also described
a doubling of the incidence of diagnosed diabetes over the
past two decades [3,4]. These trends are concerning
because of the well-documented deleterious effects of
diabetes on mortality rates, vision loss, kidney disease, am-
putation, cardiovascular diseases, and disability [5,6].
Despite these trends, major randomized controlled trials
conducted in diverse populations around the world now
provide encouraging evidence that diabetes is preventable
[7]. Specifically, among persons with impaired glucose tol-
erance (IGT), intensive lifestyle intervention reduces the
incidence of type 2 diabetes by about 50%, while the drug
metformin reduces the incidence by about 30% [8,9].
However, experts disagree on what policies would be most
effective in reducing the long-term trends in the diabetes
epidemic. Some have suggested that policies should focus
on the entire population so as to make individuals’ default
decisions healthy and require minimal individual effort
[10,11], whereas others have argued for more intensive
preventive interventions targeting higher-risk subpopula-
tions [12]. Estimation of the potential impact of different
strategies on diabetes prevalence ultimately requires in-
formation on prevalence, incidence, mortality, and
intervention effectiveness that are not available in any
single population study.
We are not aware of previous attempts to estimate the
impact of different prevention strategies on future US dia-
betes prevalence rates. In these analyses, we used a dy-
namic model based on difference equations [13] and
national diabetes prevalence, incidence, and mortality data
to estimate the impact of population-targeted and inten-
sive prevention programs on future diabetes prevalence.
Methods
We constructed a multistate epidemiologic model with a
time-varying transition matrix that divides the US adult
population into five groups: those with normal glucose
levels, those with impaired fasting glucose (IFG) (i.e., re-
gardless of IGT status), those with both IFG and IGT,
those with undiagnosed diabetes, and those with diag-
nosed diabetes. Using the model, we then estimated the
impact of the following five hypothetical diabetes pre-
vention strategies on projected diabetes prevalence rates
among US adults through 2030: 1) no intervention (in
which we assumed that current diabetes trends would
continue unabated); 2) implementation of a national
“high-risk” strategy, in which adults who have both IFG
and IGT are eligible to participate in a structured life-
style intervention; 3) implementation of a national“moderate-risk” strategy, in which adults with IFG receive
a structured lifestyle intervention; 4) implementation of a
“population-wide” strategy in which the entire US adult
population is exposed to environmental and economic
policies aimed at reducing risk factors for type 2 diabetes;
and 5) implementation of a “combined” strategy, wherein
population-wide strategies (strategy #4 above) are applied
to the entire population while the moderate-risk strategy
is simultaneously applied only to those who are identified
as having IFG (strategy #3 above).
We assumed that the moderate- and high-risk strat-
egies would result in a net 12.5% reduction in diabetes
incidence in the targeted groups. This is based on a sce-
nario in which 50% of the population is identified, 50%
agree to participate, and one-year incidence is reduced
by 50% among those who participate [14-16]. This as-
sumption was based in part on findings from studies of
hypertension control interventions [17] showing that
roughly half of the target population is usually identified
and that roughly half of those identified agree to partici-
pate in the interventions. We also conducted sensitivity
analyses in which we assumed that the net reduction in
the diabetes incidence rate would be half (i.e., 6.25%)
and twice (i.e., 25%) of this base case assumption. We
assumed that the population-wide intervention would
lead to a 2% reduction in annual diabetes incidence in
the entire US population. Because we had no data on
the effectiveness of population-wide approaches for dia-
betes prevention, we based this assumption largely on
the results of a meta-analysis of studies concerning re-
ductions in cardiovascular disease (CVD) incidence asso-
ciated with community interventions [17], which showed
an average relative net decrease in predicted CVD inci-
dence of 9.1% over an average follow-up period of
5.5 years (an average yearly net decrease of 1.8%). Other
data we considered in estimating the effectiveness of a
population-wide diabetes prevention intervention were
results of the widely referenced North Karelia Project,
which showed yearly net decreases in coronary mortality
rates of 2.2% among women and 1.1% among men asso-
ciated with community-wide cardiovascular disease risk
reduction efforts [18]. In light of these findings, we as-
sumed a 2% decline in our base case analyses, and again
conducted sensitivity analyses in which we assumed that
a population-wide intervention would reduce diabetes
annual incidence rates by half (i.e., 1%) and twice (i.e.,
4%) the amount that we assumed in our base case
analyses.
The principal data sources for our dynamic model
were the US Census Bureau, the National Diabetes Sur-
veillance System, and published findings from selected
epidemiologic studies and meta-analyses [13]. The
model’s starting estimates of the prevalence of diagnosed
diabetes, undiagnosed diabetes, IGT, and IFG among US
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from the National Health and Nutrition Examination Sur-
vey (NHANES) [19]. In NHANES, participants who
reported having received a physician’s diagnosis of diabetes
were classified as having “diagnosed diabetes”. Those with-
out diagnosed diabetes but with a fasting plasma glucose
(FPG) level ≥126 mg/dl or a two-hour postchallenge glu-
cose level ≥200 mg/dl were classified as having undiag-
nosed diabetes [20,21]. Those with an FPG level >100 mg/
dl and < 126 mg/dl were classified as having IFG, and those
with a two-hour postchallenge glucose level of 140 mg/dl
to < 200 mg/dl were classified as having IGT [20]. We used
US census estimates of the 2007 population to scale preva-
lence to the US population. All of the population surveys
used to derive our estimates underwent human subjects re-
view and obtained informed consent on all participants.
On the basis of results of a systematic review showing
annualized relative risks for diabetes associated with
IFG, IGT, and IFG and IGT combined [22] and on our
review of four prospective studies [23-26], we estimated
that the initial total diabetes incidence rate (the com-
bined rate for diagnosed and undiagnosed diabetes) in
the general US adult population was 1.22% per year. This
overall estimate was the weighted average of estimates for
adults with normal glucose levels (0.3%), those with IFG
(2.4%), and those with IFG and IGT (3.9%). Our estimates
of diabetes-related mortality rates were based on popula-
tion projections from the US Census Bureau and study re-
sults showing that the annual relative mortality risk
(relative to the risk among people without diabetes) was
1.77 among people with undiagnosed diabetes and 2.11
among those with diagnosed diabetes [27,28].
We projected future diabetes incidence rates in the
absence of any intervention using logistic growth
curves and Bayesian estimation as described by Boyle
et al. (2010) [13]. Primary analyses in this report are
based on the lower bound scenario from recently pub-
lished projections [13], roughly equivalent to a scenario
in which the current incidence rate is stabilized at
1.22% per 1,000 per year (hereafter referred to as the
“flat trend scenario”). Modeling was done using WinBUGS
software [13].
Our projections are based on the following five-state
matrix in which we define N(t) as a row vector
containing the number of people in each of the five
states at time t. B(t) is a row vector of births into each of
the states at time t. M(t) is a row vector of net migration
into each of the states. Given initial values N(2007) pro-
jections are calculated via:
N tð Þ ¼ N t−1ð ÞP tð Þ þ B tð Þ þM tð Þ:
When no intervention is applied the model is constrained
to be consistent with Census Bureau projections.We let P(t) be a transition matrix of the probabilities
of moving to or staying in each of the states at time t
given the state occupied at time t-1. At any given time
P(t) has the following form:
p11 0 p13 p14 p15
0 p22 p23 0 p25
0 p31 p33 0 p35
0 0 0 p44 p45






For example, p13 is the probability of moving to state 3
at time t given occupying state 1 at time t-1. Entries in
the matrix noted 0 are transitions that cannot occur.
Note that only the non-zero elements of P vary over
time. The rows of P sum to one minus the death rate for
the corresponding state. There were several important
assumptions of the model. First, people cannot move
from diabetes to no diabetes; this assumption is reason-
able because remission is rare [29]. Second, the relative
risks of death for the two diabetes states versus the no
diabetes state are constant over time; this assumption is
more likely to lead to a conservative estimate of the
number of future cases, because lower death rates
among people with diabetes mean greater prevalence.
Third, the assumed transition rates from non-diabetes to
diagnosed or undiagnosed diabetes are constant multiples
of the transition rate from undiagnosed to diagnosed dia-
betes. A more detailed description of these models, inc-
luding all assumptions, references for key parameter
estimates, and algebraic derivations, have been previously
published [13]. The programs for implementing the
models were written in GAUSS [30].
In sensitivity analyses, we also examine the impact of
interventions under a scenario of background incidence
of the posterior means, roughly equivalent to a continu-
ation of the rate of increase observed over the past
decade. Due to model run-time, a full Monte Carlo un-
certainty assessment of uncertainty, while desirable, is
infeasible. Therefore, we relied on a model emulation
approach to approximate the uncertainty in the number
of cases presented [31]. Details of the method appear in
the Additional file 1. Briefly, we use subjective means to
assess uncertainty in intervention effectiveness, due to
an absence of data. We treat multiple runs of the model
as though they were a sample, fit a linear model to those
runs, and use that linear model for error propagation,
using our measures of parameter uncertainty. This al-
lows us to create approximate credibility intervals.
Results
In the absence of any preventive intervention, we
projected that 51.7 million new cases of diabetes among
US adults would occur by 2030 (Table 1), that the
Table 1 Projections of cumulative diabetes incidence, diabetes prevalence, and diabetes prevalence rates through
2030 among US adults, by type of diabetes intervention strategy*
Intervention strategy 2007 2010 2015 2020 2025 2030 Change (2007 to 2030) Relative attenuation (%)
None
Cumulative diabetes incidence (millions) 2.3 6.8 17.9 29.1 40.3 51.7
Diabetes prevalence (millions) 27.8 33.1 41.2 48.7 55.3 60.7 32.9 —
Diabetes prevalence rate (%) 12.9 14.8 17.5 19.7 21.5 22.7 9.8 —
High-risk strategy (lifestyle intervention for adults with IFG and IGT)
Cumulative diabetes incidence (millions) 2.2 6.5 17.3 28.1 39.0 50.1
Diabetes prevalence (millions) 27.8 32.8 40.6 47.9 54.2 59.5 31.7 −3.6
Diabetes prevalence (%) 12.9 14.7 17.2 19.3 21.0 22.2 9.3 −5.1
Moderate-risk strategy (lifestyle intervention for adults with IFG)
Cumulative diabetes incidence (millions) 2.1 6.2 16.4 26.7 37.1 47.7
Diabetes prevalence (millions) 27.8 32.5 39.8 46.6 52.6 57.6 29.8 −9.4
Diabetes prevalence rate (%) 12.9 14.5 16.9 18.8 20.3 21.5 8.6 −12.2
Population strategy (risk reduction policies targeting entire population)
Cumulative diabetes incidence (millions) 2.2 6.7 17.6 28.5 39.6 50.8
Diabetes prevalence (millions) 27.8 33.0 40.9 48.2 54.7 60.0 32.2 −2.1
Diabetes prevalence rate (%) 12.9 14.7 17.3 19.5 21.2 22.4 9.5 −3.1
Combination of moderate-risk and population strategies
Cumulative diabetes incidence (millions) 2.0 6.1 16.1 26.3 36.7 47.1
Diabetes prevalence (millions) 27.8 32.4 39.6 46.3 52.2 57.1 29.3 −10.9
Diabetes prevalence rate (%) 12.9 14.5 16.8 18.7 20.2 21.3 8.4 −14.3
*The high-risk strategies are assumed to result in a net 12.5% reduction in diabetes incidence in the 8.3% of the population who have both IFG and IGT. The
moderate-risk strategy is assumed to result in a 12.5% reduction in the 26.7% of the population who have either IFG or IGT. The population strategy is assumed to
result in a net 2% reduction in diabetes incidence in the entire population. The combined strategy results in a 12.5% reduction in those with IFG or IGT and a 2%
reduced incidence in diabetes in the rest of the population.
Figure 1 Projected diabetes prevalence rates among US adults
according to five prevention policy scenarios, 2007 to 2030.
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diagnosed) would increase from 27.8 million in 2007 to
60.7 million in 2030, and that the diabetes prevalence
rate among US adults would increase from 12.9% to
22.7% during this period.
We projected that the combined strategy would be the
most effective and that its implementation would result in
4.6 million fewer new diabetes cases through 2030, reduce
the prevalence of diabetes in 2030 by 3.6 million cases,
and reduce the diabetes prevalence rate in 2030 from
22.7% to 21.3%. Our other projections indicated that the
moderate-risk approach (intervention for the 26.7% of the
population with IFG) would result in 4.0 million fewer
new diabetes cases over 20 years, reduce the diabetes
prevalence in 2030 by 3.1 million cases, and reduce the
diabetes prevalence rate in 2030 from 22.7% to 21.5%. The
high-risk approach (intervention for the 8.3% of the popu-
lation with both IFG and IGT) would reduce the projected
2030 prevalence of diabetes by 1.2 million cases and re-
duce the projected prevalence rate in 2030 from 22.7% to
22.2%. The population-wide approach would have a
projected impact similar to the high-risk approach, redu-
cing 0.9 million cumulative cases, 0.7 million prevalentcases in the year 2030, and reducing the prevalence rate in
2030 from 22.7% to 22.4% (Table 1; Figure 1). Even if the
most effective strategy is implemented (the combined
strategy), our projections indicate that the diabetes preva-
lence rate would increase by about 65% over the 20 years
(i.e., from 12.9% in 2010 to 21.3% in 2030). Compared
with the projected increase in diabetes prevalence in the
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cate that the relative attenuation in the increase in preva-
lence would be 5.1%, 12.2%, 3.1%, and 14.3% with
implementation of the high-risk, moderate-risk, popula-
tion, and combined scenarios, respectively.
We also projected that implementation of the com-
bined intervention would reduce the diagnosed diabetes
prevalence rate in 2030 by 0.8 percentage points (from
16.3% to 15.5%), reduce the undiagnosed diabetes preva-
lence rate by 0.5 percentage points, but increase the pre-
dicted pre-diabetes prevalence rate by 0.9 percentage
points (Figure 2). The projected lower prevalence of per-
sons with normal glucose levels (low risk) and with pre-
diabetes occurred because the incidence of diabetes was
higher, which shifted persons out of the low-risk and
prediabetes categories.
In a one-variable-at-a-time sensitivity analysis, in
which we assumed that the diabetes incidence rate
among US adults would continue to increase according
to recent trends (roughly 60% increase over the past
20 years, i.e., the middle range scenario described by
Boyle et al., [11]), we found that the relative benefits of
the alternative prevention strategies were similar to what
we projected them to be in our base case analyses
(Table 2). However, if assumed that the structured life-
style intervention would reduce the incidence rate in the
target population by 6.25% rather than 12.5%, or that the
population-wide intervention would reduce the popula-
tion incidence rate by 4% rather than 2%, then the
population-wide approach would be slightly more bene-
ficial than the high-risk approach. However, even under


































Figure 2 Projected prevalence rates of normal glucose tolerance, pre
US adults from 2010 through 2030 if no national diabetes prevention
is implemented.population-wide approach, we projected that its imple-
mentation would reduce the number of diabetes cases
by only about half as much as the moderate-risk ap-
proach and only about a third as much as the combined
approach.
Finally, the results of our error propagation analysis
appear in Table 3. The intervals are relatively wide, due
to the substantial uncertainty in the effectiveness of a
hypothetical intervention, particularly a population-wide
intervention. However, even with the large uncertainty
the combined scenarios would result in a net reduction
in diabetes prevalence over what would occur with no
intervention, but diabetes prevalence would still increase
over its current level.
Discussion
Results of several controlled trials have shown that lifestyle
interventions can reduce the incidence of type 2 diabetes
among people at high risk [7-9,16,32]. Questions remain,
however, about the impact of these targeted interventions,
as well as those of population-wide interventions, on fu-
ture diabetes incidence and prevalence rates. Although
drawing definitive conclusions is difficult, due to param-
eter uncertainty, our model suggested that the greatest
reduction in the number of diabetes cases would be
achieved through implementation of a multitiered strategy
involving a structured lifestyle intervention for adults with
IFG in conjunction with risk-reduction policies aimed at
the entire population. We projected that such an approach
would result in 4.6 million fewer diabetes cases over 20
years and 3.6 million (14%) fewer Americans with diabetes




diabetes, undiagnosed diabetes, and diagnosed diabetes among
intervention is implemented and if the combined intervention
Table 2 Results of one-variable-at-a-time sensitivity analyses showing effects of changes in two base case assumptions
on the projected reduction in diabetes prevalence among US adults in 2030 following implementation of four
diabetes prevention strategies











Flat background diabetes incidence rate* 1.2 [3.1] 0.5 [1.2] 0.3 [0.7] 1.4 [3.6]
Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in
target population
Population-wide intervention will reduce the yearly diabetes incidence rate
by 2% among all US adults
Adjustments to base case assumptions
Increasing background incidence rate* 1.4 [3.7] 0.5 [1.4] 0.3 [0.8] 1.6 [4.2]
Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in
target population
2.5 [6.4] 1.0 [2.6] 0.3 [0.7] 2.7 [6.9]
Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in
target population
0.6 [1.5] 0.3 [0.6] 0.3 [0.7] 0.8 [2.0]
Population-wide intervention will reduce yearly diabetes incidence rate by
1% among all US adults
1.2 [3.1] 0.5 [1.2] 0.2 [0.3] 1.1 [2.8]
Population-wide intervention will reduce yearly diabetes incidence rate by
4% among all US adults
1.2 [3.1] 0.5 [1.2] 0.6 [1.4] 1.6 [4.0]
*Flat background diabetes incidence estimated at 1.22% per year. Increasing background diabetes incidence rate estimated based on the middle incidence
projection from Boyle et al., wherein incidence increases by 75% between 2007 and 2050.
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reductions are substantial given the high lifetime risk of
amputation, kidney disease, and CVD and the extensive
lifetime health care costs among people with diagnosed
diabetes [33,34]. We projected that the next most effective
strategy—and possibly the most plausible one under a set-
ting of limited resources—would be the moderate-risk
strategy (a lifestyle intervention for about 27% of the
population), which we projected would result in a 12.2%
attenuation in what we projected the increase in diabetes
prevalence would be in the absence of any additional dia-
betes prevention intervention. We projected that the high-
risk approach would produce a prevalence reduction only
about one-third as large as the combined approach and
that the population-wide approach would produce aTable 3 Uncertainty for the projected reduction in
diabetes prevalence for four intervention scenarios
Intervention (r2 for linear
model approximation)
95% approximate credibility interval
for projected reduction in diabetes
prevalence, compared to no
intervention (millions)
Combined (0.92) 0.9 to 6.3
Population (0.93) 0.0 to 0.91
High-risk (0.91) 0.0 to 3.01
Moderate-risk (0.93) 0.1 to 5.9
1Due to their approximate nature, the calculated lower bounds of these
intervals were small negative numbers. Since it is not plausible that
interventions could increase prevalence, we have truncated these intervals
at 0.0.prevalence reduction only about one-fourth as large; for
both of these scenarios, our error propagation analysis re-
minds us that even these gains are somewhat uncertain.
Our projection that the population-wide approach, by it-
self, would be relatively ineffective was in part because our
assumption about the risk reduction to be derived was
lower, but also because most people receiving the inter-
vention would not have developed diabetes anyway.
Despite the benefits that can be achieved with prevent-
ive interventions, particularly the combined and
moderate-risk approaches, our projections indicate a
need to develop new options for diabetes prevention
and/or increase the reach of both primary and secondary
prevention efforts. We projected that the diabetes preva-
lence rate in the United States will surpass 20% by 2030
even if the combined strategy is implemented; a large in-
crease in prevalence will occur even at the upper cred-
ibility bound for effectiveness of this intervention, the
most optimistic plausible case. This projected increase
was based on data showing a steady increase in the US
diabetes incidence rate over the past 20 years [35,36], a
decline in diabetes mortality rates as diabetes has be-
come increasingly treatable while remaining largely in-
curable [4,37], and transition of the baby boom
generation into the age range corresponding to peak dia-
betes incidence [38].
Our projection that the US diabetes prevalence rate
will increase substantially even under the combined
intervention scenario indicates that the success of
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minish the need for more effective programs to help
people manage their diabetes and prevent its complica-
tions. Diabetes has diffuse effects, leading to multiple
microvascular and macrovascular complications and an
increased risk for aging-related disability. Because nu-
merous clinical, screening, community, and educational
interventions reduce the incidence of complications
[39,40], many diabetes experts have argued that delivery
of proven interventions is more important for the dia-
betic population than the development of new therapies
[41]. Our findings similarly indicate the importance of
timely and efficient screening and treatment for hyper-
tension, hyperlipidemia, chronic kidney disease, and dia-
betic eye and foot disease among people with diagnosed
diabetes, especially as people with diabetes live longer
with the condition. We should remember, however, that
such success in the reduction of diabetes complications
will likely lead to lower diabetes mortality rates and thus
can contribute to an increase in diabetes prevalence.
Our projections are limited by our assumptions. If the
US diabetes incidence rate continues to increase at its
recent pace (rather than stabilizing at the 2007 rate, as
we assumed in our primary analyses) and all other as-
sumptions are unchanged, the prevalence of diabetes in
2030 would be three to four percentage points higher
than we projected [13]. If mortality rates associated with
diabetes decline over time, as suggested by the results of
some studies [4,42], and all other assumptions are un-
changed, the prevalence of diabetes in 2030 would also
be higher than we projected. Our conclusions about the
relative impact of various intervention policies on fu-
ture diabetes prevalence rates would be relatively un-
affected by changes in our assumptions about future
diabetes incidence rates. However, our model also ref-
lected our assumption that the interventions would
have no effect on diabetes mortality rates other than
their effect on diabetes risk. Any additional reductive ef-
fect on mortality rates associated with the interventions
would actually result in smaller differences in diabetes
prevalence projections among the intervention scenar-
ios than those we reported. Perhaps the biggest practical
limitation of our model is that it did not allow us to
project diabetes prevalence by age, sex, or racial/ethnic
group. Because the absolute prevalence of diabetes is
much higher and more influenced by mortality rates
among older adults than among younger adults, inter-
ventions could be more effective in reducing future dia-
betes prevalence rates among younger adults than our
projections indicated they would be for the overall US
adult population. Similarly, the prevalence rates among
younger adults could stabilize or even decrease even
though the prevalence rate among all US adults con-
tinues to rise.As indicated by both our one-variable-at-a-time and
error propagation analyses, our findings are sensitive to
our assumptions about the effectiveness of interventions.
Results of several randomized controlled trials among
people with prediabetes have found a 50% or more re-
duction in incidence among people with prediabetes,
with some finding extended effects up to 20 years later
[9,16,32,43]. Similar levels of weight loss among people
with prediabetes as those seen in the diabetes prevention
trials have been observed in interventions provided in
community settings with economically sustainable staff
and facilities [44-46]. In the absence of data that would
support a more complicated assumption, we made the
simple assumption that the relative risk reduction asso-
ciated with lifestyle intervention was the same in people
with IFG as those with both IFG and IGT. However, our
modeling did account for differences in the absolute risk
between risk strata that would, in turn, lead to different
levels of absolute risk reduction in response to an inter-
vention. The accuracy of our projections was also
dependent on the extent to which the “rule of halves” that
has been reported in hypertension studies, wherein about
half of the target population would be identified and re-
ferred to a lifestyle program and about half of those re-
ferred would actually initiate participation in a lifestyle
program, is also applicable to diabetes lifestyle interven-
tions [14]. However, even if these assumptions are correct,
the moderate- and high-risk approaches would require a
strong system of reimbursement for providers of commu-
nity lifestyle programs that does not yet exist.
The impact of a population-wide approach to diabetes
prevention is particularly hard to predict because there
have been few estimates of the health impact of such an
approach; this is reflected in the large uncertainty in this
term in our error propagation analysis. We based our esti-
mates that population-wide strategies would lead to a 1 to
4% reduction in the relative incidence of diabetes on the
results of studies concerning community-based efforts to
reduce rates of CVD [17,47]. Given the strong relationship
between obesity and diabetes, the success of a population-
wide approach to diabetes prevention will ultimately de-
pend on the extent to which such an approach is success-
ful in reducing obesity rates [48]. Proposed approaches to
doing this include taxing sugared beverages or sugar itself,
mandating wide-scale menu labeling, providing incentives
to increase the availability of healthy foods, encouraging
urban designs that promote physical activity, and enhan-
cing awareness of and education about risk factors and
prevention behaviors [49-51]. Programs to enhance
employer-based health-promotion programs also may help
reduce diabetes rates, particularly if they can effectively
stratify the population by levels of diabetes risk and the in-
tensity of the intervention appropriate for that risk level
[17,49-51]. Since these interventions could have important
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hypertension, cardiovascular disease, and disability, the
pure focus of our analysis on prevention of diabetes cases
may not reflect the value or the differential impact of the
hypothetical interventions. Finally, the feasibility of any
intervention depends on both effectiveness and cost. Real
interventions similar to the hypothetical ones described
here could have vastly different costs. However, due to the
structure of our model, the scarcity of the literature, and
the lack of details as to how national interventions like the
ones we describe might be implemented, it was not feas-
ible for us to consider cost in our estimates.
Although our projections of future diabetes preva-
lence rates among US adults are based on numerous
assumptions, they are likely more accurate than previ-
ous projections because they are based on more recent
data, including updated projections of future diabetes
incidence rates and updated population projections.
Most importantly, because the model we used esti-
mated diabetes incidence and mortality rates for people
at different stages of diabetes risk and in different diag-
nostic categories, it allowed us to more accurately pro-
ject the impact of various intervention strategies.
However, our projections, and others like these, need
to be continuously updated as new intervention effect-
iveness and epidemiologic data become available. We
hope that more rigorous controlled studies or perhaps
natural experiments of population-targeted approaches
for diabetes prevention will emerge in the future to
permit more confident modeling of the impact on fu-
ture prevalence.
The results of our analyses indicate a need for the
provision of effective lifestyle interventions to the large
number of adults with prediabetes as well as support
research aimed at improving the effectiveness of these
interventions. They also suggest a need for research
designed to improve the effectiveness of population-
wide approaches to diabetes prevention. Unless both
strategies are much more effective than we assumed
they will be in our analyses, the prevalence of diabetes
among US adults will continue to increase even if the
US health care system adopts something like the com-
bined diabetes prevention strategy that we described.
This continued increase in diabetes prevalence will re-
sult in an increase in demands for diabetes manage-
ment and treatment, including services related to the
prevention of diabetes complications and diabetes-
related disability, and these services will need to be
strengthened along with primary diabetes prevention
efforts.
The findings and conclusions in this report are those
of the authors and do not necessarily represent the offi-
cial positions of the Centers for Disease Control and
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